-DOCSTART- -X- O
This -X- _ O
article -X- _ O
is -X- _ O
a -X- _ O
non-systematic -X- _ O
review -X- _ O
of -X- _ O
selected -X- _ O
recent -X- _ O
publications -X- _ O
in -X- _ O
community-acquired -X- _ B-Patient
pneumonia -X- _ I-Patient
, -X- _ O
including -X- _ O
a -X- _ O
comparison -X- _ O
of -X- _ O
various -X- _ O
guidelines. -X- _ O
Risk -X- _ O
stratification -X- _ O
of -X- _ O
patients -X- _ O
has -X- _ O
recently -X- _ O
been -X- _ O
advanced -X- _ O
by -X- _ O
the -X- _ O
addition -X- _ O
of -X- _ O
several -X- _ O
useful -X- _ O
biomarkers. -X- _ O
The -X- _ O
issue -X- _ O
of -X- _ O
single -X- _ O
versus -X- _ O
dual -X- _ O
antibiotic -X- _ O
treatment -X- _ O
remains -X- _ O
controversial -X- _ O
and -X- _ O
awaits -X- _ O
a -X- _ O
conclusive -X- _ O
randomized -X- _ O
controlled -X- _ O
trial. -X- _ O
However -X- _ O
, -X- _ O
in -X- _ O
the -X- _ O
meantime -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
a -X- _ O
working -X- _ O
consensus -X- _ O
that -X- _ O
more -X- _ O
severe -X- _ O
patients -X- _ O
should -X- _ O
receive -X- _ O
dual -X- _ O
therapy -X- _ O
. -X- _ O

